National and Kapodistrian University of Athens
Η φαρμακοκινητική της τιγεκυκλίνης μετά από χορήγηση off-label δόσης σε ασθενείς της ΜΕΘ με πνευμονία
Abstract
dc:descriptionIntroduction Tigecycline is commonly used for infections by multidrug-resistant bacteria. However, it is not approved for ventilator-associated pneumonia (VAP) as increased mortality has been reported in VAP patients treated with conventional doses (100 mg loading dose, followed by 50 mg every 12 hours). Purpose The purpose of this study was to evaluate the intrapulmonary pharmacokinetics of off-label, high-dose tigecycline in ICU patients with VAP. Materials and Methods This was a prospective, open-label study of pharmacokinetics undertaken in the Department of Critical Care in University Hospital ATTIKON in collaboration with the Center for Anti-Infective Research & Development at Hartford Hospital (Hartford, CT, USA).Tigecycline was administered intravenously with a loading dose 200 mg followed by 100 mg every 12 h. After ≥5 doses, two bronchoscopies were performed in each patient on consecutive days and eight blood samples were collected. Tigecycline concentrations in plasma and bronchoalveolar lavage fluid were determined by liquid chromatography. The urea dilution method was used to calculate epithelial lining fluid (ELF) concentrations. A two-compartmental pharmacokinetic (PK) model with linear elimination was used to estimate PK parameters. Results Nine mechanically ventilated patients were included. Mean patient age was 69 ± 11.86 years and mean APACHE II score was 21. The estimated population mean PK parameters (relative standard error) were: clearance, 11.64 L/h (54%); volume of distribution in central compartment, 79.01 L (37%); volume of distribution in peripheral compartment, 92.95 L (17%); intercompartmental clearance, 62.81 L/h (34%); and ELF penetration ratio, 2.41 (40%). Maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), plasma area under the concentration–time curve (AUC0-12), plasma freeAUC0-12 and ELF AUC0-12 were 1.99 ± 1.82 μg/mL, 0.81 ± 1.27 μg/mL, 12.89 ± 17.25 μg•h/mL, 3.24 ± 3.09 μg•h/mL and 7.13 ± 2.61 μg•h/mL, respectively. Conclusion The increased plasma and ELF AUC0-12 achieved with a 200 mg daily tigecycline dose, combined with high ELF penetration, support the effectiveness of off-label high-dose tigecycline in VAP.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Almyroudi, Maria-Panagiota
- Αλμυρούδη, Μαρία-Παναγιώτα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59510